Table 2. Summary of participant demographics for each type of adherence behaviour.

Characteristic	Total cohort	Discontinued after a short time	Adherence
			≥97%	<97% ≥80%	<80% with drug holidays	<80% with variable dosing
		Type 1	Type 2	Type 3	Type 4	Type 5
No. (%) Male (n=88)	46 (53%)	6 (67%)	9 (53%)	15 (50%)	7 (78%)	9 (45%)
Median age, years (IQR) (n=88)	72 (63, 78)	68 (64, 68)	74 (71, 79)	72 (65, 78)	73 (67, 78)	72 (63, 78)
No. (%) employed (n=82)	21 (27%)	3 (33%)	5 (29%)	1 (3%)	4 (44%)	8 (40%)
No. (%) married/partner (n=81)	59 (73%)	5 (56%)	11 (65%)	25 (83%)	5 (56%)	13 (65%)
No. (%) left school at 16 years (n=80)	43 (54%)	4 (44%)	10 (59%)	17 (57%)	3 (33%)	9 (45%)
No. (%) with family members with glaucoma (n=70)	48 (67%)	1 (11%)	2 (6%)	9 (30%)	2 (22%)	9 (45%)
No. (%) uses other medication (n=76)	62 (82%)	6 (67%)	14 (82%)	20 (67%)	8 (89%)	14 (70%)
No. (%) uses other medication at same time as travoprost (n=62)	14 (23%)	1 (11%)	3 (18%)	6 (20%)	1 (11%)	3 (15%)
No. (%) encountered problems using travoprost (n=75)	27 (36%)	4 (44%)	3 (18%)	10 (33%)	5 (56%)	5 (25%)
No. (%) needed help to administer travoprost (n=76)	20 (26%)	2 (22%)	5 (29%)	7 (23%)	2 (22%)	4 (20%)
No. (%) sought further advice (n=75)	24 (32%)	2 (22%)	3 (18%)	37 (17%)	2 (22%)	6 (30%)